Verrica Pharmaceuticals Inc. (NASDAQ: VRCA) today announced that the first patient has been enrolled in the company’s Phase 2 ‘CARE’ ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Corporate News FDA Management Comments

Verrica Pharmaceuticals Enrolls First Patient in Phase 2 Trial of VP-102 for the Treatment of External Genital WartsJune 27, 2019 4:01 PM Verrica Pharmaceuticals (VRCA) PT Raised to $23 at H.C. WainwrightJune 27, 2019 10:44 AM UPDATE: Vocera Communications (VCRA) PT Raised to $23 at H.C. Wainwright, CORRECTIONJune 27, 2019 10:42 AM Pre-Open Movers 06/27: (DOVA) (ZGNX) (OFG) (AAOI) (ACRS) (CAG) (RAD) (BA) (more)June 27, 2019 9:01 AM After-Hours Movers 06/26 (OFG) (VRCA) (MLHR) Higher; (ACRS) (RAD) (MOTS) (more...)June 26, 2019 5:49 PM Verrica Pharmaceuticals (VRCA) to Resume Trading at 4:30 pm ETJune 26, 2019 4:14 PM Verrica (VRCA) Phase 2 Clinical Study of VP-102 in Patients with Common Warts Achieved Primary EndpointJune 26, 2019 4:03 PM